Biohaven: NDA Review Of Troriluzole Isn't Only 2025 Catalyst On Deck
Biohaven's NDA for Troriluzole was accepted by the FDA, potentially leading to approval in Q3 2025. Click here to find out ...
Managed Healthcare Executive16 天
FDA Approves Journavx, New Nonopioid Med, for Acute Pain
The FDA recently approved Vertex Pharmaceuticals Incorporated’s Journavx (suzetrigine), a first-in-class non-opioid medication for treating moderate to severe acute pain in adults. Journavx, approved ...
eLife18 天
Disentangling acute motor deficits and adaptive responses evoked by the loss of cerebellar ...
Cerebellar patients exhibit various motor impairments, but the sequence of primary and compensatory processes leading to these deficits remains unclear. To investigate this, we reversibly blocked ...